IKT supply chain intelligence for Inhibikase Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Inhibikase Therapeutics, Inc. (IKT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CORHEPTA-PHARMACEUTICALS-INC | CORHEPTA-PHARMACEUTICALS-INC | 90% | Pursuant to the Merger Agreement, we paid consideration for CorHepta of $15.0 million, subject to a customary purchase price adjustment mechanism. |
| SPHAERA-PHARMA-PTE-LTD | SPHAERA-PHARMA-PTE-LTD | 80% | On March 2, 2012, we entered into a collaborative research and development agreement ("Sphaera Agreement"), with Sphaera Pharma Pte. Ltd. |
| DNLI | Denali Therapeutics Inc. | 72% | Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: Reciprocal relationship from DNLI gra… |
| DNLI | Denali Therapeutics Inc. | 72% | tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IKT graph: o build a sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with ou… |
| ORANY | ORANY | 72% | o build a sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.… |
| PRTA | Prothena Corporation plc | 72% | tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl… |
| PRTA | Prothena Corporation plc | 72% | Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT graph: Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate m… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable co… |
| SNYNF | Sanofi | 72% | tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ABLI-THERAPEUTICS-INC | ABLI-THERAPEUTICS-INC | 90% | In exchange for the exclusive license rights, ABLi made a non-refundable, non-creditable payment of one dollar. |
| DNLI | Denali Therapeutics Inc. | 72% | tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl… |
| DNLI | Denali Therapeutics Inc. | 72% | Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cos… |
| GOSS | Gossamer Bio, Inc. | 72% | file of our products following approval; • effective competition with other therapies including, without limitation, competing with much larger companies who may possess more capital, experience and … |
| GOSS | Gossamer Bio, Inc. | 72% | Reciprocal relationship from GOSS graph: Reciprocal relationship from IKT graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from IKT graph: file of our products following approv… |
| ORANY | ORANY | 72% | o build a sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IKT graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IKT graph: o build a sales, marketing, and com… |
| PRTA | Prothena Corporation plc | 72% | Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cos… |
| PRTA | Prothena Corporation plc | 72% | tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IKT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate… |
| SNYNF | Sanofi | 72% | tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl… |
| CO-LLC | CO-LLC | 62% | alize any product candidates we may develop, and our technology may be adversely affected. Risks Related to Our Business, Financial Condition and Capital Requirements We are a clinical-stage drug dev… |
| CORHEPTA-PHARMACEUTICALS-INC | CORHEPTA-PHARMACEUTICALS-INC | 62% | of those awards over the requisite service period, which is generally the vesting period of the respective award. We estimate the fair value of stock options granted to our employees and directors on… |
| PROJECT-IKT-MERGER-SUB-INC | PROJECT-IKT-MERGER-SUB-INC | 62% | of those awards over the requisite service period, which is generally the vesting period of the respective award. We estimate the fair value of stock options granted to our employees and directors on… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IKT-DEBT-10222 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-28. |
| IKT-DEBT-10221 | Warrants outstanding: 1937985 | 90% | xbrl warrant detail from xbrl 2023-03-31. |
| IKT-DEBT | Debt stack $381,784 | 90% | Market cache reports total debt of $381,784. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IKT-OWNER-SANDS-CAPITAL-ALTERNATIVES-LLC | Sands Capital Alternatives, LLC | 90% | 13F overlay lists Sands Capital Alternatives, LLC as top holder; 104 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| PRTA | Prothena Corporation plc | 100.00 | 1 | ['customer', 'supplier'] |
| XOMAP | XOMA Royalty Corporation | 100.00 | 2 | |
| GOSS | Gossamer Bio, Inc. | 100.00 | 1 | ['customer'] |
| LQDA | Liquidia Corporation | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| DNLI | Denali Therapeutics Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| BFRIW | Biofrontera Inc. | 50.00 | 2 | |
| AMXOF | AMERICA MOVIL SAB DE CV/ | 50.00 | 2 | |
| BLRX | BioLineRx Ltd. | 50.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 50.00 | 2 | |
| D | Dominion Energy, Inc. | 50.00 | 2 | |
| CMCM | Cheetah Mobile Inc. | 50.00 | 2 |